Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts

Yuhan Wang, Craig Dorrell, Willscott (Scott) Naugler, Michael Heskett, Paul Spellman, Bin Li, Feorillo Galivo, Annelise Haft, Leslie Wakefield, Markus Grompe

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Direct lineage reprogramming can convert readily available cells in the body into desired cell types for cell replacement therapy. This is usually achieved through forced activation or repression of lineage-defining factors or pathways. In particular, reprogramming toward the pancreatic β cell fate has been of great interest in the search for new diabetes therapies. It has been suggested that cells from various endodermal lineages can be converted to β-like cells. However, it is unclear how closely induced cells resemble endogenous pancreatic β cells and whether different cell types have the same reprogramming potential. Here, we report in vivo reprogramming of pancreatic ductal cells through intra-ductal delivery of an adenoviral vector expressing the transcription factors Pdx1, Neurog3, and Mafa. Induced β-like cells are mono-hormonal, express genes essential for β cell function, and correct hyperglycemia in both chemically and genetically induced diabetes models. Compared with intrahepatic ducts and hepatocytes treated with the same vector, pancreatic ducts demonstrated more rapid activation of β cell transcripts and repression of donor cell markers. This approach could be readily adapted to humans through a commonly performed procedure, endoscopic retrograde cholangiopancreatography (ERCP), and provides potential for cell replacement therapy in type 1 diabetes patients. β cell regeneration has been of great interest in diabetes research. Wang et al. describe an intra-ductal injection approach to reprogram pancreatic ducts into insulin-producing β cells and rescue diabetes in mouse models. This work provides important insights into the mechanism of reprogramming and offers a promising therapeutic strategy for type 1 diabetes.

Original languageEnglish (US)
JournalMolecular Therapy
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Pancreatic Ducts
Cell- and Tissue-Based Therapy
Type 1 Diabetes Mellitus
Endoscopic Retrograde Cholangiopancreatography
Essential Genes
Hyperglycemia
Regeneration
Hepatocytes

Keywords

  • Diabetes
  • Gene therapy
  • Insulin
  • Liver
  • Mafa
  • Neurog3
  • Pancreas
  • Pdx1
  • Reprogramming
  • β cell

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery

Cite this

Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts. / Wang, Yuhan; Dorrell, Craig; Naugler, Willscott (Scott); Heskett, Michael; Spellman, Paul; Li, Bin; Galivo, Feorillo; Haft, Annelise; Wakefield, Leslie; Grompe, Markus.

In: Molecular Therapy, 01.01.2018.

Research output: Contribution to journalArticle

Wang, Yuhan ; Dorrell, Craig ; Naugler, Willscott (Scott) ; Heskett, Michael ; Spellman, Paul ; Li, Bin ; Galivo, Feorillo ; Haft, Annelise ; Wakefield, Leslie ; Grompe, Markus. / Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts. In: Molecular Therapy. 2018.
@article{460026692f15402683a33771e8013fa4,
title = "Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts",
abstract = "Direct lineage reprogramming can convert readily available cells in the body into desired cell types for cell replacement therapy. This is usually achieved through forced activation or repression of lineage-defining factors or pathways. In particular, reprogramming toward the pancreatic β cell fate has been of great interest in the search for new diabetes therapies. It has been suggested that cells from various endodermal lineages can be converted to β-like cells. However, it is unclear how closely induced cells resemble endogenous pancreatic β cells and whether different cell types have the same reprogramming potential. Here, we report in vivo reprogramming of pancreatic ductal cells through intra-ductal delivery of an adenoviral vector expressing the transcription factors Pdx1, Neurog3, and Mafa. Induced β-like cells are mono-hormonal, express genes essential for β cell function, and correct hyperglycemia in both chemically and genetically induced diabetes models. Compared with intrahepatic ducts and hepatocytes treated with the same vector, pancreatic ducts demonstrated more rapid activation of β cell transcripts and repression of donor cell markers. This approach could be readily adapted to humans through a commonly performed procedure, endoscopic retrograde cholangiopancreatography (ERCP), and provides potential for cell replacement therapy in type 1 diabetes patients. β cell regeneration has been of great interest in diabetes research. Wang et al. describe an intra-ductal injection approach to reprogram pancreatic ducts into insulin-producing β cells and rescue diabetes in mouse models. This work provides important insights into the mechanism of reprogramming and offers a promising therapeutic strategy for type 1 diabetes.",
keywords = "Diabetes, Gene therapy, Insulin, Liver, Mafa, Neurog3, Pancreas, Pdx1, Reprogramming, β cell",
author = "Yuhan Wang and Craig Dorrell and Naugler, {Willscott (Scott)} and Michael Heskett and Paul Spellman and Bin Li and Feorillo Galivo and Annelise Haft and Leslie Wakefield and Markus Grompe",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ymthe.2018.02.014",
language = "English (US)",
journal = "Molecular Therapy",
issn = "1525-0016",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Long-Term Correction of Diabetes in Mice by In Vivo Reprogramming of Pancreatic Ducts

AU - Wang, Yuhan

AU - Dorrell, Craig

AU - Naugler, Willscott (Scott)

AU - Heskett, Michael

AU - Spellman, Paul

AU - Li, Bin

AU - Galivo, Feorillo

AU - Haft, Annelise

AU - Wakefield, Leslie

AU - Grompe, Markus

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Direct lineage reprogramming can convert readily available cells in the body into desired cell types for cell replacement therapy. This is usually achieved through forced activation or repression of lineage-defining factors or pathways. In particular, reprogramming toward the pancreatic β cell fate has been of great interest in the search for new diabetes therapies. It has been suggested that cells from various endodermal lineages can be converted to β-like cells. However, it is unclear how closely induced cells resemble endogenous pancreatic β cells and whether different cell types have the same reprogramming potential. Here, we report in vivo reprogramming of pancreatic ductal cells through intra-ductal delivery of an adenoviral vector expressing the transcription factors Pdx1, Neurog3, and Mafa. Induced β-like cells are mono-hormonal, express genes essential for β cell function, and correct hyperglycemia in both chemically and genetically induced diabetes models. Compared with intrahepatic ducts and hepatocytes treated with the same vector, pancreatic ducts demonstrated more rapid activation of β cell transcripts and repression of donor cell markers. This approach could be readily adapted to humans through a commonly performed procedure, endoscopic retrograde cholangiopancreatography (ERCP), and provides potential for cell replacement therapy in type 1 diabetes patients. β cell regeneration has been of great interest in diabetes research. Wang et al. describe an intra-ductal injection approach to reprogram pancreatic ducts into insulin-producing β cells and rescue diabetes in mouse models. This work provides important insights into the mechanism of reprogramming and offers a promising therapeutic strategy for type 1 diabetes.

AB - Direct lineage reprogramming can convert readily available cells in the body into desired cell types for cell replacement therapy. This is usually achieved through forced activation or repression of lineage-defining factors or pathways. In particular, reprogramming toward the pancreatic β cell fate has been of great interest in the search for new diabetes therapies. It has been suggested that cells from various endodermal lineages can be converted to β-like cells. However, it is unclear how closely induced cells resemble endogenous pancreatic β cells and whether different cell types have the same reprogramming potential. Here, we report in vivo reprogramming of pancreatic ductal cells through intra-ductal delivery of an adenoviral vector expressing the transcription factors Pdx1, Neurog3, and Mafa. Induced β-like cells are mono-hormonal, express genes essential for β cell function, and correct hyperglycemia in both chemically and genetically induced diabetes models. Compared with intrahepatic ducts and hepatocytes treated with the same vector, pancreatic ducts demonstrated more rapid activation of β cell transcripts and repression of donor cell markers. This approach could be readily adapted to humans through a commonly performed procedure, endoscopic retrograde cholangiopancreatography (ERCP), and provides potential for cell replacement therapy in type 1 diabetes patients. β cell regeneration has been of great interest in diabetes research. Wang et al. describe an intra-ductal injection approach to reprogram pancreatic ducts into insulin-producing β cells and rescue diabetes in mouse models. This work provides important insights into the mechanism of reprogramming and offers a promising therapeutic strategy for type 1 diabetes.

KW - Diabetes

KW - Gene therapy

KW - Insulin

KW - Liver

KW - Mafa

KW - Neurog3

KW - Pancreas

KW - Pdx1

KW - Reprogramming

KW - β cell

UR - http://www.scopus.com/inward/record.url?scp=85043491880&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043491880&partnerID=8YFLogxK

U2 - 10.1016/j.ymthe.2018.02.014

DO - 10.1016/j.ymthe.2018.02.014

M3 - Article

JO - Molecular Therapy

JF - Molecular Therapy

SN - 1525-0016

ER -